We are pleased to announce that our firm has successfully advised Aurobindo Pharma in the establishment of its Malaysian subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. This new entity, incorporated through Helix Healthcare B.V., represents a strategic step in Aurobindo’s expansion into Southeast Asia and will support their pharmaceutical products business in Malaysia.

Aurobindo Pharma is a globally recognized leader in the pharmaceutical industry, with deep expertise in active pharmaceutical ingredients (APIs), formulation development, and robust R&D capabilities. Their integrated global manufacturing footprint and commitment to innovation position them strongly to meet the evolving needs of healthcare markets worldwide.

Our dedicated team on this transaction comprised Senior Partner Dato’ Azmi Mohd Ali, Associate Amir Fahmi Annas, and Trainee Solicitor Muhammad Danial Azli.

We are proud to have supported Aurobindo Pharma in this important venture and we look forward to continuing support as the Malaysian operations mature and grow. Here’s to more cross-border collaborations and enabling impactful growth in the life sciences sector.

For more information on this news, please visit:
– https://lnkd.in/d_bEWKpu
– https://lnkd.in/gSv_XbCQ

Corporate Communications
Azmi & Associates
7 October 2025